Search results
One stock is dragging down the S&P 500's earnings growth
AOL· 3 days agoCompanies in the S&P 500 (^GSPC) have reported what's broadly been considered a solid Q1 earnings season for the index, with one key exception: drugmaker Bristol Myers Squibb (BMY). Last month ...
One stock is dragging down the S&P 500's earnings growth
Yahoo Finance· 3 days agoWhen removing a few other companies from the sector, the S&P 500's earnings growth would shoot even...
3 candidates vying for Macon-Bibb County Commission’s District 3 seat. Here’s who they are
Macon Telegraph via Yahoo News· 3 days agoI pledge as a future commissioner, to remain independent from special interests and...and around...
Jennifer Hudson Receives GLAAD Ally Award, 17 Years After Presenting It to Patti LaBelle
People Magazine· 4 days agoThe 35th Annual GLAAD Media Awards, honoring fair and inclusive LGBTQ+ representation in the media,...
Google’s New Workplace AI Bot Underscores Big Tech’s Enterprise Focus
PYMNTS.com· 1 day agoAlready, OpenAI held an event of its own on Monday (May 13), where the artificial intelligence (AI)...
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its...
FOX21 Colorado Springs· 8 hours agoCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the online publication of a peer reviewed ...
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 7 days agoArcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call Transcript May 8, 2024 Arcus Biosciences,...
'They're ferocious' | Keller neighbors suffer series of attacks by pair of nesting hawks
WFAA Dallas-Fort Worth· 7 days agoSitting high above a tree in the Mount Gilead community of Keller is a hawk nest. Over the last...
Nipocalimab's Unique Mechanism Gets Second Chance in RA
Medscape· 4 days agoThe IRIS-RA study of the investigational monoclonal antibody drug nipocalimab in patients with...
US FDA approves expanded use of Bristol Myers' cancer cell therapy (May 15)
AOL· 22 hours agoThe Food and Drug Administration's decision marks the fourth approval for Breyanzi, which can now be used to treat follicular lymphoma patients who have received two or more prior lines of therapy ...